DUBLIN--(BUSINESS WIRE)--The "Pulmonary Arterial Hypertension (PAH) - Market Insights, Epidemiology and Market Forecast-2027" report has been added to ResearchAndMarkets.com's offering.
Pulmonary Arterial Hypertension (PAH) - Market Insights, Epidemiology and Market Forecast - 2027 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of AC in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs having the potential to get launched in the forecast period, market share of the individual therapies, and current and forecasted market size of Pulmonary Arterial Hypertension (PAH) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Key Topics Covered:
1. Key Insights
2. Pulmonary Arterial Hypertension (PAH) Market Overview at a Glance
3. Disease Background and Overview: Pulmonary Arterial Hypertension (PAH)
4. Epidemiology and Patient Population
5. Country Wise-Epidemiology of Pulmonary Arterial Hypertension (PAH)
6. Treatment Algorithm
7. Unmet Needs
8. Marketed Drugs
9. Marketed Drugs by Companies
10. Safety and Efficacy of Marketed Drugs
11. Emerging Therapies
12. Global Market Size of Pulmonary Arterial Hypertension (PAH)
13. Pulmonary Arterial Hypertension (PAH): 7 Major Market Analysis
14. Pulmonary Arterial Hypertension (PAH): Market Outlook by Region
15. United States
16. EU5 Countries
17. Rest of World (ROW)
18. Rest of Europe (ROE)
19. Market Drivers
20. Market Barriers
21. Appendix
22. Capabilities
Companies Mentioned
- United Therapeutics Corporation
- Actelion Pharmaceuticals Ltd.
- GSK
- Bayer AG
- Pfizer
For more information about this report visit https://www.researchandmarkets.com/research/prfvwq/pulmonary?w=4
